Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Metadoxine Extended Release in Adolescents with PI-ADHD
NCT02189772Phase 2Completed
- Sponsor
- Alcobra Ltd.
- Start
- Aug 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Metadoxine in attention deficit hyperactivity disorder (ADHD), sponsored by Alcobra Ltd.. Started Aug 2014; status: completed.
02
Drugs
Metadoxine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02189772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02189772.